Gene Therapy Sample Clauses

Gene Therapy. The electronic versions of (a) the most recent print edition of Gene Therapy; and (b) all previous print editions of Gene Therapy that were first published within the previous four (4) years, from the later of the Commencement Date or the most recent of any subsequent Renewal Date (both as defined herein), but in any event all editions first published since the Commencement Date, in each case as available for access on the Internet at the URL ▇▇▇▇://▇▇▇.▇▇▇▇▇▇.▇▇▇/gt together with any additional material that the Licensor makes available to the Licensee.
View SourceView Similar (8)
Gene Therapy. Students will learn the history of gene therapy and the principal concepts behind gene therapy applications. We will cover the early gene therapy failures and the important lessons learned from these studies, which led to modified strategies based upon improved understanding of genetic components and how this knowledge led to successful translation for the treatment of human diseases like genetic disorders and cancer. Genome Editing: Students will be introduced to genome editing technologies, including transcription activator-like effector nucleases (TALENs), zinc-finger nucleases (ZFNs) and clustered regularly interspaced short palindromic repeats (CRISPR)-associated nuclease Cas9. Bioinformatics: Students will get an overview of bioinformatics resources for analysis of protein sequences. They will be introduced to immunomic and infectivity databases and learn how to deal with immunogenicity analysis. Assessment method Emerging Viral Infections: Discovery and Intervention Strategies Organization: Hannover Medical School Teaching unit coordinator: Teaching unit coordinator: ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇▇ Teaching unit outline Topics addressed
View SourceView Similar (4)
Gene Therapy. 4 1.16 Genentech Knowhow........................................................5 1.17 Genentech Manufacturing Knowhow..........................................5 1.18 Genentech Patent Rights..................................................5 1.19 IND......................................................................6 1.20
View SourceView Similar (2)
Gene Therapy. Gene therapy remains the most promising treatment approach for most NCLs, including the transmembrane protein-deficient forms. A relatively large number of cells will need to be transduced in transmembrane protein-deficient NCLs compared to those that lack lysosomal enzymes, as the neighbouring affected cells cannot rely on cross correction from transduced cells (▇▇▇▇▇▇▇▇ et al., 2015; ▇.
View Source
Gene Therapy. Gene therapy or gene-based therapies are not covered.
View Source
Gene Therapy. During the term of the Program, Millennium and Lilly agree to discuss collaborations within the Field and the area of Oncology concerning candidates for gene therapy arising from the Program. The initial opportunity to begin such discussions concerning gene therapy shall arise when a gene that is appropriate for use in gene therapy is discovered in the course of the Millennium Research Program or a [**] and is brought to the attention of the Joint Management Team. When this occurs, the parties shall have a period of [**] in which to decide whether to begin good faith negotiations with each other concerning a potential gene therapy collaboration on such a gene. If the parties decide to Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. collaborate on a gene therapy project, the terms of such collaboration shall be governed by the terms and conditions of a separate agreement. If, either (a) a gene described in the preceding paragraph has a potential application only outside of Oncology, (b) the parties choose not to negotiate with each other concerning a collaboration within Oncology, or (c) the parties cannot agree to the terms of a collaboration within Oncology, then each party shall have a co-exclusive right to make, use and sell a Gene Therapy Drug embodying such a gene for all gene therapy applications, both within the Field and outside the Field, within the Territory. Each party shall be entitled to sublicense the co-exclusive rights to make, use and sell each Gene Therapy Drug embodying such gene to one (1) sublicensee per country. Any further licensing of the Gene Therapy Drug embodying such gene shall require the [**]. Each party shall pay the other party a [**] on its Net Sales of the Gene Therapy Product within the Territory. All royalty payments shall be made subject to the provisions of Article VIII of this Agreement. In the event that the total royalty burden of any Gene Therapy Product sold by a party is greater than [**] of the Net Sales of the Gene Therapy Product in the Territory (inclusive of the [**] paid under the terms of this Section 5.3), then that party's royalty payable to the other party shall [**] of the excess over [**] paid by that party; provided, however, the royalty payment to the other party shall not fall below [**] of Net Sales of the Gene Therapy Product in the Territory. Nothing within this Section 5.3 grants Millennium any rights to Candidate Gene...
View Source

Related to Gene Therapy

  • Speech Therapy This plan covers speech therapy services when provided by a qualified licensed • loss of speech or communication function; or • impairment as a result of an acute illness or injury, or an acute exacerbation of a chronic disease. Speech therapy services must relate to: • performing basic functional communication; or • assessing or treating swallowing dysfunction. See Autism Services when speech therapy services are rendered as part of the treatment of autism spectrum disorder. The amount you pay and any benefit limit will be the same whether the services are provided for habilitative or rehabilitative purposes.

  • Therapies Acupuncture and acupuncturist services, including x-ray and laboratory services. • Biofeedback, biofeedback training, and biofeedback by any other modality for any condition. • Recreational therapy services and programs, including wilderness programs. • Services provided in any covered program that are recreational therapy services, including wilderness programs, educational services, complimentary services, non- medical self-care, self-help programs, or non-clinical services. Examples include, but are not limited to, Tai Chi, yoga, personal training, meditation. • Computer/internet/social media based services and/or programs. • Recreational therapy. • Aqua therapy unless provided by a physical therapist. • Maintenance therapy services unless it is a habilitative service that helps a person keep, learn or improve skills and functioning for daily living. • Aromatherapy. • Hippotherapy. • Massage therapy rendered by a massage therapist. • Therapies, procedures, and services for the purpose of relieving stress. • Physical, occupational, speech, or respiratory therapy provided in your home, unless through a home care program. • Pelvic floor electrical and magnetic stimulation, and pelvic floor exercises. • Educational classes and services for speech impairments that are self-correcting. • Speech therapy services related to food aversion or texture disorders. • Exercise therapy. • Naturopathic, homeopathic, and Christian Science services, regardless of who orders or provides the services. • Eye exercises and visual training services. • Lenses and/or frames and contact lenses for members aged nineteen (19) and older. • Vision hardware purchased from a non-network provider. • Non-collection vision hardware. • Lenses and/or frames and contact lenses unless specifically listed as a covered healthcare service.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.